The Risks of Open Payments – Validate Spend Reports With Data Analytics Prior To Submission

With the next filing period for spend data under the Sunshine Act coming up, pharma companies are going to be responsible for making sure that the data they submit to CMS is accurate, complete and free of data anomalies. In the slides below, you will get to learn about the implications of public availability of Open Payments data, the ways in which it can be used by government authorities to initiate enforcement actions, and most importantly, how you can evaluate your spend before CMS submission through data analytics to ensure it doesn’t contain questionable transactions.

 


OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.